A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis

Journal of the Neurological Sciences

Volumn 237, Issue 1-2, 2005, Pages 75-81

  Matsuzaki, Toshio ^a   Saito, Mineki ^a   Usuku, Koichiro ^a   Nose, Hirohisa ^a   Izumo, Shuji ^b   Arimura, Kimiyoshi ^a   Osame, Mitsuhiro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

HAM TSP; HTLV 1; Immunomodulation; Lactobacillus casei strain Shirota; NK cell activity

Indexed keywords

PROBIOTIC AGENT;

ADULT; ARTICLE; BACTERIAL STRAIN; CELL SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FERMENTED PRODUCT; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; LACTOBACILLUS CASEI; MALE; MICTURITION DISORDER; MILK; MOTOR PERFORMANCE; NATURAL KILLER CELL; NEUROLOGIC EXAMINATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; RATING SCALE; SPASTIC PARAPLEGIA; SPINAL CORD INFECTION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANIMALS; DELTARETROVIRUS ANTIBODIES; DISABILITY EVALUATION; FEMALE; FERMENTATION; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LACTOBACILLUS CASEI; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MILK; MUSCLE SPASTICITY; PARAPARESIS, TROPICAL SPASTIC; PHENOTYPE; PROBIOTICS; PROSPECTIVE STUDIES; URINATION DISORDERS; VIRAL LOAD;

EID: 25644435010     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2005.05.011     Document Type: Article

References (41)

1. M. Osame, K. Usuku, S. Izumo, N. Ijichi, H. Amitani, and A. Igata HTLV-I associated myelopathy, a new clinical entity Lancet 1 1986 1031 1032
2. A. Gessain, F. Barin, J.C. Vernant, O. Gout, L. Maurs, and A. Calender Antibodies to human T-lymphotropic virus type-1 in patients with tropical spastic paraparesis Lancet 2 1985 407 410
3. M. Nakagawa, S. Izumo, S. Ijichi, H. Kubota, K. Arimura, and M. Kawabata HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings J Neurovirol 4 1998 586 593
4. M. Nagai, K. Usuku, W. Matsumoto, D. Kodama, N. Takenouchi, and T. Moritoyo Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP J Neurovirol 4 1998 586 593
5. M. Mori, K. Kinoshita, N. Ban, Y. Yamada, and H. Shiku Activated T-lymphocyte with polyclonal gammopathy in patients with human T-lymphotropic virus type I-associated myelopathy Ann Neurol 24 1988 280 282
6. S. Ijichi, N. Eiraku, M. Osame, S. Izumo, R. Kubota, and I. Maruyama Activated T lymphocytes in cerebrospinal fluid of patients with HTLV-I-associated myelopathy (HAM/TSP) J Neuroimmunol 25 1989 251 254
7. Y. Itoyama, S. Minato, J. Kira, I. Goto, H. Sato, and K. Okochi Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy Neurology 38 1988 1302 1307
8. S. Jacobson, V. Zaninovic, C. Mora, P. Rodgers-Johnson, W.A. Sheremata, and C.J. Gibbs Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis Ann Neurol 23 1988 S196 S200
9. N. Eiraku, S. Ijichi, S. Yashiki, M. Osame, and S. Sonoda Cell surface phenotype of in vitro proliferating lymphocytes in HTLV-I-associated myelopathy (HAM/TSP) J Neuroimmunol 37 1992 223 228
10. I. Elovaara, S. Koenig, A.Y. Brewah, R.M. Woods, T. Lehky, and S. Jacobson High human T cell lymphotropic virus type 1 (HTLV-I)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-I-associated neurological disease J Exp Med 117 1993 1567 1573
11. T.F. Greten, J.E. Slansky, R. Kubota, S.S. Soldan, E.M. Jaffee, and T.P. Leist Direct visualization of antigen-specific T cells: HTLV-I Tax11-19-specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients Proc Natl Acad Sci U S A 95 1998 7568 75673
12. M. Nagai, Y. Yamano, M.B. Brennan, C.A. Mora, and S. Jacobson Increased HTLV-I provirus load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP Ann Neurol 50 2001 807 812
13. R. Kubota, T. Kawanishi, H. Matsubara, A. Manns, and S. Jacobson Demonstration of human T lymphotropic virus type I (HTLV-I) Tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection J Immunol 161 1998 482 488
14. K.J. Jeffery, K. Usuku, S.E. Hall, W. Matsumoto, G.P. Taylor, and J. Procter HLA alleles determine human T-lymphotropic virus-I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy Proc Natl Acad Sci U S A 96 1999 3848 3853
15. M. Osame, M. Matsumoto, K. Usuku, S. Izumo, N. Ijichi, and H. Amitani Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells Ann Neurol 21 1987 117 122
16. M. Osame, A. Igata, M. Matsumoto, M. Kohka, K. Usuku, and S. Izumo HTLV-I-associated myelopathy (HAM). Treatment trials, retrospective survey, and clinical and laboratory findings Hematol Rev 3 1990 271 284
17. H. Matsuo, T. Nakamura, M. Tsujihata, I. Kinoshita, A. Satoh, and I. Tomita Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy Lancet 2 1988 1109 1113
18. T. Nakamura, K. Shibayama, K. Nagasato, H. Matsuo, M. Tsujihata, and S. Nagataki The efficacy of interferon-alpha treatment in human T-lymphotropic virus type-I-associated myelopathy Jpn J Med 29 1990 362 367
19. Y. Kuroda, K. Kurohara, F. Fujiyama, H. Takashima, C. Endo, and M. Matsui Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy Acta Neurol Scand 86 1992 82 86
20. K. Yamasaki, J. Kira, Y. Koyanagi, Y. Kawano, N. Miyano-Kurosaki, and M. Nakamura Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study J Neurol Sci 147 1997 135 144
21. S. Izumo, I. Goto, Y. Itoyama, T. Okajima, S. Watanabe, and Y. Kuroda Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial Neurology 46 1996 1016 1021
22. M. Saito, M. Nakagawa, S. Kaseda, T. Matsuzaki, M. Jonosono, and N. Eiraku Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis J Infect Dis 189 2004 29 40
23. T. Matsuzaki Immunomodulation by treatment with Lactobacillus casei strain Shirota Int J Food Microbiol 41 1998 133 140
24. S. Miake, K. Nomoto, T. Yokokura, Y. Yoshikai, M. Mutai, and K. Nomoto Protective effect of Lactobacillus casei on Pseudomonas aeruginosa infection in mice Infect Immun 48 1985 480 485
25. I. Kato, T. Yokokura, and M. Mutai Augmentation of mouse natural killer cell activity by Lactobacillus casei and its surface antigens Microbiol Immunol 27 1984 209 217
26. I. Kato, T. Yokokura, and M. Mutai Correlation between increase in Ia-bearing macrophages and induction of T cell-dependent antitumor activity by Lactobacillus casei in mice Cancer Immunol Immunother 26 1988 215 221
27. A. Takagi, T. Matsuzaki, M. Sato, K. Nomoto, M. Morotomi, and T. Yokokura Inhibitory effect of oral administration of Lactobacillus casei on 3-methylchoranthrene-induced carcinogenesis in mice Med Microbiol Immunol 188 1999 111 116
28. I. Kato, K. Endo-Tanaka, and T. Yokokura Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritis in DBA/1 mice Life Sci 63 1998 635 644
29. K. Nomoto, S. Miake, S. Hashimoto, T. Yokokura, M. Mutai, and Y. Yoshikai Augmentation of host resistance to Listeria monocytogenes infection by Lactobacillus casei J Clin Lab Immunol 17 1985 91 97
30. T. Watanabe, and H. Saito Protection of mice against herpes simplex virus infection by a Lactobacillus casei preparation (LC9018) in combination with inactivated viral antigen Microbiol Immunol 30 1986 111 122
31. H. Yasui, J. Kiyoshima, and T. Hori Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota Clin Diagn Lab Immunol 11 2004 675 679
32. K. Fujihara, Y. Itoyama, F. Yu, C. Kubo, and I. Goto Cellular immune surveillance against HTLV-I infected T lymphocytes in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) J Neurol Sci. 105 1991 99 107
33. F. Yu, Y. Itoyama, K. Fujihara, and I. Goto Natural killer (NK) cells in HTLV-I-associated myelopathy/tropical spastic paraparesis-decrease in NK cell subset populations and activity in HTLV-I seropositive individuals J Neuroimmunol 33 1991 121 128
34. M. Saito, V.M. Braud, P. Goon, E. Hanon, G.P. Taylor, and A. Saito Low frequency of CD94/NKG2A+ T lymphocytes in patients with HTLV-1-associated myelopathy/ tropical spastic paraparesis, but not in asymptomatic carriers Blood 102 2003 577 584
35. M. Osame Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP W.A. Blattner Human Retrovirology 1990 Raven Press New York 191 197
36. R.W. Bohannon, and M.B. Smith Interrater reliability of a modified Ashworth scale of muscle spasticity Phys Ther 67 1987 206 207
37. D. Hamann, P.A. Baars, M.H. Rep, B. Hooibrink, S.R. Kerkhof-Garde, and M.R. Klein Phenotypic and functional separation of memory and effector human CD8+ T cells J Exp Med 186 1997 1407 1418
38. Y. Aso, and H. Akazan Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer, BLP Study Group Urol Int 49 1992 125 129
39. F. Nagao, M. Nakayama, T. Muto, and K. Okumura Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the immune system in healthy human subjects Biosci Biotechnol Biochem 64 2000 2706 2708
40. M. Takahashi, S. Iwata, N. Yamazaki, and H. Fujiwara Phagocytosis of the lactic acid bacteria by M cells in the rabbit Payer's patches J Clin Electron Microsc 24 1991 5 6
41. A.R. French, and W.M. Yokoyama Natural killer cells and viral infections Curr Opin Immunol 15 2003 45 51